TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) is now available.
Pharmaron Beijing Co., Ltd. reported its interim results for the six months ending June 30, 2025, showing a 14.9% increase in revenue to approximately RMB6,441.0 million compared to the same period in 2024. Despite the revenue increase, the profit attributable to owners of the parent decreased by 37.0% to approximately RMB701.4 million, and the company decided not to declare an interim dividend. The net cash flows from operating activities increased by 28.1%, indicating strong operational cash generation.
The most recent analyst rating on (HK:3759) stock is a Buy with a HK$22.00 price target. To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock, see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company is focused on providing a range of services including drug discovery, development, and manufacturing to its clients.
Average Trading Volume: 14,162,105
Technical Sentiment Signal: Buy
Current Market Cap: HK$53.9B
See more data about 3759 stock on TipRanks’ Stock Analysis page.